Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Bahri

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Drug Safety|November 17, 2010
Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategiesPriya Bahri
Vaccine|December 18, 2018
CIOMS Guide To Vaccine Safety Communication - Executive summaryPriya Bahri, Lembit Rägo,
Drug Safety|September 16, 2021
Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and DiscoursePriya Bahri, Antoine Pariente
European Journal of Clinical Pharmacology|June 27, 2019
'Engagement' of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological frameworkPatrick Brown, Priya Bahri
Pharmacoepidemiology and Drug Safety|November 2, 2004
Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH)Priya Bahri, Panos Tsintis
British Journal of Clinical Pharmacology|March 25, 2018
Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulatorsPriya Bahri, Mireia Castillon Melero
Drug Safety|September 15, 2012
How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug MonitoringPriya Bahri, Mira Harrison-Woolrych
Drug Safety|October 16, 2012
Focusing on risk communication about medicines: why now?Priya Bahri, Mira Harrison-Woolrych
BMC Medicine|May 4, 2017
Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccinesPriya Bahri, Julianna Fogd, Daniel Morales, et al.
Drug Safety|October 6, 2017
An Update on ISoP Special Interest Groups (SIGs)Deirdre McCarthy, Priya Bahri, Joanne Barnes, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Drug Safety|November 17, 2010
Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategiesPriya Bahri
Vaccine|December 18, 2018
CIOMS Guide To Vaccine Safety Communication - Executive summaryPriya Bahri, Lembit Rägo,
Drug Safety|September 16, 2021
Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and DiscoursePriya Bahri, Antoine Pariente
European Journal of Clinical Pharmacology|June 27, 2019
'Engagement' of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological frameworkPatrick Brown, Priya Bahri
Pharmacoepidemiology and Drug Safety|November 2, 2004
Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH)Priya Bahri, Panos Tsintis
British Journal of Clinical Pharmacology|March 25, 2018
Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulatorsPriya Bahri, Mireia Castillon Melero
Drug Safety|September 15, 2012
How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug MonitoringPriya Bahri, Mira Harrison-Woolrych
Drug Safety|October 16, 2012
Focusing on risk communication about medicines: why now?Priya Bahri, Mira Harrison-Woolrych
BMC Medicine|May 4, 2017
Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccinesPriya Bahri, Julianna Fogd, Daniel Morales, et al.
Drug Safety|October 6, 2017
An Update on ISoP Special Interest Groups (SIGs)Deirdre McCarthy, Priya Bahri, Joanne Barnes, et al.
Pageof 4